ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
Q1 2025 vs. Q4 2024
How the institutions holding ARS Pharmaceuticals, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 166 | 2 | 184 | +20 |
| Shares | 71.3M | 1.09M | 76.2M | +6.02M (+8.6%) |
| Value | $752.3M | $11.5M | $958.9M | +$218.2M (+29.5%) |
2 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (41)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
Sold out (21)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Bank of Montreal | 340,591 | $3.59M |
| Qube Research & Technologies Ltd | 130,289 | $1.37M |
| Jacobs Levy Equity Management, Inc | 101,397 | $1.07M |
| Connor, Clark & Lunn Investment Management Ltd. | 80,641 | $850.8K |
| Wealth Enhancement Advisory Services, LLC | 60,294 | $636.1K |
| Panoramic Capital, LLC | 45,806 | $483.3K |
| STRS Ohio | 24,000 | $253.2K |
| Jane Street Group, LLC | 21,154 | $223.2K |
| Wolverine Trading, LLC | 20,763 | $220.5K |
| Aigen Investment Management, LP | 20,515 | $216.4K |
| PEAK6 LLC | 15,350 | $161.9K |
| Compass Capital Corp | 10,000 | $133.9K |
| Freestone Grove Partners LP | 12,501 | $131.9K |
| Graham Capital Management, L.P. | 12,469 | $131.5K |
| Group One Trading, L.P. | 10,916 | $115.2K |
| Ancora Advisors, LLC | 6,000 | $63.3K |
| Caitong International Asset Management Co., Ltd | 4,028 | $42.5K |
| Federated Hermes, Inc. | 473 | $4.99K |
| Aspect Partners, LLC | 200 | $2.11K |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 50 | $527 |
| EverSource Wealth Advisors, LLC | 5 | $53 |
Not filed for Q1 2025 yet (2)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nextech Invest AG | 936,729 | $9.88M |
| Nuveen Asset Management, LLC | 157,951 | $1.67M |